The tumorigenesis in BCC is ligand-independent as the pathway is constitutively activated via mutations in the components of the HH pathway, including activating mutations in the SMO or inactivating mutations in the PTCH1 or SUFU [1]. This evidence concerns the gene PTCH1 and skin basal cell carcinoma.